GLP-1 Market
LLY $1170.14 ▲ +0.5% NVO $39.40 ▼ -1.0% PFE $27.93 ▲ +0.7% VKTX $40.85 ▲ +35.7% KLRA $12.79 ▲ +6.7% GPCR $36.91 ▲ +0.3% RHHBY $55.56 ▲ +0.5%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

CBL-514

CBL-514

Company
Caliway Biopharmaceuticals Co., Ltd.
Mechanism
Mechanism not yet reported
Route
Injectable
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 23, 2026

Find a Clinical Trial Near Me

See recruiting studies for CBL-514 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07140939

    A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat

    Not yet reported Caliway Biopharmaceuticals Co., Ltd. 320 participants Est. completion 2027-09 13 sites Stand-alone
    Other conditions: Subcutaneous Fat
    View official trial listing →
  • Recruiting NCT NCT07608770

    A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

    Not yet reported Caliway Biopharmaceuticals Co., Ltd. 250 participants Est. completion 2027-11 1 site Stand-alone
    Other conditions: Subcutaneous Fat
    View official trial listing →
  • Completed NCT NCT04575467

    A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

    Not yet reported Caliway Biopharmaceuticals Co., Ltd. 25 participants Est. completion 2021-12-08 1 site Stand-alone
    Other conditions: Subcutaneous Fat
    View official trial listing →
  • Completed NCT NCT04698642

    A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat

    Not yet reported Caliway Biopharmaceuticals Co., Ltd. 43 participants Est. completion 2020-11-12 1 site Stand-alone
    Other conditions: Subcutaneous Fat
    View official trial listing →
  • Completed NCT NCT04699669

    A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers

    Not yet reported Caliway Biopharmaceuticals Co., Ltd. 40 participants Est. completion 2019-08-20 1 site Stand-alone
    Other conditions: Subcutaneous Fat
    View official trial listing →
  • Completed NCT NCT04897412

    A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)

    Not yet reported Caliway Biopharmaceuticals Co., Ltd. 75 participants Est. completion 2023-03-22 5 sites Stand-alone
    Other conditions: Subcutaneous Fat
    View official trial listing →
  • Completed NCT NCT05234736

    A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers

    Not yet reported Caliway Biopharmaceuticals Co., Ltd. 10 participants Est. completion 2022-06-09 1 site Stand-alone
    Other conditions: Subcutaneous Fat
    View official trial listing →
  • Completed NCT NCT05387733

    A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas

    Not yet reported Caliway Biopharmaceuticals Co., Ltd. 12 participants Est. completion 2023-04-03 1 site Stand-alone
    Other conditions: Dercum's Disease
    View official trial listing →
  • Completed NCT NCT05632926

    A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)

    Not yet reported Caliway Biopharmaceuticals Co., Ltd. 12 participants Est. completion 2023-05-03 2 sites Stand-alone
    Other conditions: Cellulite
    View official trial listing →
  • Completed NCT NCT05736107

    A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

    Not yet reported Caliway Biopharmaceuticals Co., Ltd. 107 participants Est. completion 2024-05-20 1 site Stand-alone
    Other conditions: Subcutaneous Fat
    View official trial listing →
  • Completed NCT NCT05836779

    A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)

    Not yet reported Caliway Biopharmaceuticals Co., Ltd. 23 participants Est. completion 2024-01-05 5 sites Stand-alone
    Other conditions: Cellulite
    View official trial listing →
  • Completed NCT NCT06005441

    A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.

    Not yet reported Caliway Biopharmaceuticals Co., Ltd. 173 participants Est. completion 2024-10-18 1 site Stand-alone
    Other conditions: Subcutaneous Fat
    View official trial listing →
  • Completed NCT NCT06303570

    A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas

    Not yet reported Caliway Biopharmaceuticals Co., Ltd. 19 participants Est. completion 2026-04-14 1 site Stand-alone
    Other conditions: Dercum's Disease
    View official trial listing →
  • Not yet recruiting NCT NCT07526974

    A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )

    Not yet reported Caliway Biopharmaceuticals Co., Ltd. 320 participants Est. completion 2027-10 14 sites Stand-alone
    Other conditions: Subcutaneous Fat
    View official trial listing →
  • Not yet recruiting NCT NCT07608757

    A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

    Not yet reported Caliway Biopharmaceuticals Co., Ltd. 250 participants Est. completion 2028-06 1 site Stand-alone
    Other conditions: Subcutaneous Fat
    View official trial listing →
  • Not yet recruiting NCT NCT07733947

    A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

    Not yet reported Caliway Biopharmaceuticals Co., Ltd. 300 participants Est. completion 2028-09 1 site Stand-alone
    Other conditions: Subcutaneous Fat
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: CBL-514, CBL-514 injection

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.